San Francisco, 08 January, HIV Diagnostics Market Analysis By Product
(Antibody Tests, Viral Identification Assays, CD4 Testing, Viral Load Testing,
Early Infant Diagnosis) And Segment Forecasts To 2022
Global HIV Diagnostics Market is expected to reach USD
4.48 billion by 2022, growing at an estimated CAGR of 9.5% from 2015 to 2022,
according to a new study by Grand View Research, Inc. Key factors accounting
for the growth of this market include the growing need in for the development
of more sensitive HIV diagnostic point of care tests which can be easily
implemented at the location of patient care in resource limited settings.
Technological development of tests which is expected to introduce a number of
novel rapid, point-of-care tests throughout the forecast period is a primary
factor expected to fuel the growth of the HIV diagnostics market. Furthermore,
government programs and campaigns initiated against HIV, global healthcare
efforts to reduce disease incidence, and the presence of high unmet demand in
the Middle Eastern and Eastern regions of the market are some key factors
expected to serve as lucrative future growth opportunities.
Access Full Research
Report On HIV Diagnostics Market Analysis:
Further key findings from the study suggest:
·
Antibody HIV diagnostic tests
accounted for the largest share of the market in 2014. This large share can be
accounted for by the high market usage and penetration rates of these tests
which include, ELISA, home access dried blood spot, western blot testing IFA
and RIPA. These tests are highly sensitive and accurate and thus are most
commonly used for screening and confirmation of HIV-1 & HIV-2.
·
Viral Load testing and CD4
testing also accounted for a considerable share of the market in 2014. There is
a prevalent in the market for the development of these tests which will make
them more sensitive, rapid in nature and portable to the point of care to
enhance their market usability and accessibility in resource limited HIV
affected regions.
·
It is expected that during the
forecast period a number of novel point of care HIV diagnostic products will be
commercialized which are currently under clinical development and in product
pipelines of key market players. This increase in the range of products s
expected to fuel the growth of this market over the forecast period.
·
North America was observed to
account for the largest share of the market in 2014, which can be attributed to
the presence of a strong healthcare R&D scenario in which the presence of
government funding and ongoing corporate efforts to enhance product portfolio
are anticipated to accelerate the timelines for new product development.
Furthermore, the presence of favorable reimbursements policies for HIV and
other infectious diseases is also a factor accounting for this region’s large
share.
·
Asia Pacific is expected to
grow at a relatively faster rate over the forecast period owing to, the
presence of high levels of unmet market demand for HIV screening and testing.
Moreover, collaborations among market participants from the western regions is
another significant expected to boost the growth of Asia Pacific HIV
diagnostics market during the forecast period.
·
Key players of the market
include Janssen Diagnostics, Daktari Diagnostics, Cepheid, Hologic and Chembio
Diagnostic Systmes Inc.
Browse More Reports Of This Category By
Grand View Research At: www.grandviewresearch.com/industry/clinical-diagnostics
Grand View Research has segmented the HIV
diagnostics market on the basis of product and region:
HIV Diagnostics Product Outlook
(Revenue, USD Million, 2012 - 2022)
·
Antibody Tests
o
HIV-1 Screening Tests
o ELISA/EIA
o Home Access Dried Blood Spot
o Rapid Tests (Dot plot, Agglutination Tests)
o
HIV-1 Antibody Confirmatory
Tests
o Western Blot Test
o Indirect Immunofluorescent Antibody Assay (IFA)
o Line Immunoassay
o RadioImmunoPrecipitation Assay (RIPA)
o
HIV-2 & Group O Diagnostic
Tests
o Blood Antibody Tests
o Dried Blood Spot (DBS) Test
o Others and (Oral, Urine)
·
Viral Identification Assays
o
P24 Antigen Test
o
Qualitative PCR Tests
o
Viral Culture
·
CD4 Testing
·
Viral Load Testing
·
Early Infant Diagnostics
HIV Diagnostics Regional
Outlook (Revenue, USD Million, 2012 - 2022)
·
North America
o
U.S.
o U.S. HIV Diagnostics Market, by Product
o
Canada
o Canada HIV Diagnostics Market, by Product
·
Europe
o
Germany
o Germany HIV Diagnostics Market, by Product
o
UK
o UK HIV Diagnostics Market, by Product
·
Asia Pacific
o
Japan
o Japan HIV Diagnostics Market, by Product
o
China
o China HIV Diagnostics Market, by Product
·
Latin America
o
Brazil
o Brazil HIV Diagnostics Market, by Product
·
MEA
o
South Africa
o South Africa HIV Diagnostics Market, by Product
Access Full Press Release of this Report:
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and
consulting company, registered in the State of California and headquartered in
San Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
For more information: www.grandviewresearch.com/
